BACKGROUND: Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI. METHODS: Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay. RESULTS: Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P = .0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P = .06). Liver function test (LFT) elevations occurred in 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group. Mortality and length of stay were consistent with historical controls. CONCLUSIONS: RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.
BACKGROUND: Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI. METHODS: Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay. RESULTS: Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P = .0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P = .06). Liver function test (LFT) elevations occurred in 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group. Mortality and length of stay were consistent with historical controls. CONCLUSIONS: RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.
Authors: Yasar Caliskan; Seyedmahdi Pahlavani; Ariel Schnell; Aliza Anwar Memon; Fadee Abu Al Rub; Usama Elewa; Marie Philipneri; Kana Miyata; Thanh-Mai Vo; Amy Mosman; Thomas Groll; John Edwards; Krista L Lentine Journal: Turkish J Nephrol Date: 2022-07
Authors: E Leegwater; D J A R Moes; L B E Bosma; T H Ottens; I M van der Meer; C van Nieuwkoop; E B Wilms Journal: Antimicrob Agents Chemother Date: 2022-06-01 Impact factor: 5.938
Authors: Lavanya Yohanathan; Cristina C Campioli; Omar Y Mousa; Kymberly Watt; Daniel Z P Friedman; Vijay Shah; Resham Ramkissoon; Alexander S Hines; Patrick S Kamath; Raymund R Razonable; Andrew D Badley; Erin S DeMartino; Michael J Joyner; Rondell Graham; Paschalis Vergidis; Doug A Simonetto; William Sanchez; Timucin Taner; Julie K Heimbach; Elena Beam; Michael D Leise Journal: Am J Transplant Date: 2021-05-05 Impact factor: 9.369
Authors: Ramy H Elshaboury; Miranda M Monk; Lisa M Bebell; Monique R Bidell; Meagan L Adamsick; Ronak G Gandhi; Molly L Paras; Elizabeth L Hohmann; Alyssa R Letourneau Journal: Ther Adv Infect Dis Date: 2021-09-22
Authors: Dorota Zarębska-Michaluk; Jerzy Jaroszewicz; Magdalena Rogalska; Beata Lorenc; Marta Rorat; Anna Szymanek-Pasternak; Anna Piekarska; Aleksandra Berkan-Kawińska; Katarzyna Sikorska; Magdalena Tudrujek-Zdunek; Barbara Oczko-Grzesik; Beata Bolewska; Piotr Czupryna; Dorota Kozielewicz; Justyna Kowalska; Regina Podlasin; Krzysztof Kłos; Włodzimierz Mazur; Piotr Leszczyński; Bartosz Szetela; Katarzyna Reczko; Robert Flisiak Journal: J Clin Med Date: 2021-05-10 Impact factor: 4.241
Authors: Susan A Olender; Theresa L Walunas; Esteban Martinez; Katherine K Perez; Antonella Castagna; Su Wang; Dax Kurbegov; Parag Goyal; Diego Ripamonti; Bindu Balani; Francesco G De Rosa; Stéphane De Wit; Shin-Woo Kim; George Diaz; Raffaele Bruno; Kathleen M Mullane; David Chien Lye; Robert L Gottlieb; Richard H Haubrich; Anand P Chokkalingam; George Wu; Helena Diaz-Cuervo; Diana M Brainard; I-Heng Lee; Hao Hu; Lanjia Lin; Anu O Osinusi; Jose I Bernardino; Marta Boffito Journal: Open Forum Infect Dis Date: 2021-05-26 Impact factor: 3.835